Journal of Investigative Medicine High Impact Case Reports (Nov 2021)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

  • Yukinobu Watanabe MD, PhD,
  • Masahiro Ogawa MD, PhD,
  • Yu Tamura MD,
  • Seiichiro Suda MD,
  • Masahiro Kaneko MD,
  • Mariko Kumagawa MD,
  • Midori Hirayama MD,
  • Naoki Matsumoto MD, PhD,
  • Toshiki Yamamoto MD, PhD,
  • Mitsuhiko Moriyama MD, PhD

DOI
https://doi.org/10.1177/23247096211058489
Journal volume & issue
Vol. 9

Abstract

Read online

A 74-year-old man was diagnosed with hepatocellular carcinoma. The tumor in the liver showed a complete response after transcatheter arterial chemoembolization, but lung, bone, and lymph node metastases were observed, so treatment with atezolizumab plus bevacizumab was initiated. After administration, the scans showed tumor growth, but after continuous administration of atezolizumab plus bevacizumab, the tumors finally reduced in size and showed a partial response. The transient growth of the tumors was considered to be pseudoprogression. Herein, we report a case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.